2009년 8월 일 - Yonsei University · 2020. 7. 3. · E/Aratio 1.4±1.0 1.0±0.5 0.04 E/E'...

년 월 일2009 8

983193

983193

983193

- i -

국문요약 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotⅳ

서 론Ⅰ middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 1

재료 및 방법Ⅱ middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 2

연구대상1 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 2

자료수집 방법 및 심부전의 정의2 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 2

자료 처리 및 통계분석3 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 5

결 과Ⅲ middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 6

연구대상 환자의 임상적 특성1 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 6

수축기 심부전과 이완기 심부전의 임상양상의 비교2 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 6

사망률 호전 여부와 관련된 인자3 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 8

수축기 심부전과 이완기 심부전 환자의 생존분석 결과4 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 8

고 찰Ⅳ middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 10

결 론V middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 13

참고문헌 middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 14

Abstract middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 18

- ii -

Table 1 Clinical characteristics of systolic and diastolic heart failure

patients middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 20

Table 2 Echocardiographic finding of systolic heart failure and diastolic

heart failure patients middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 21

Table 3 Laboratory finding of systolic heart failure and diastolic heart

failure patients middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 22

Table 4 Comparisons of various factors between survival and death group

in systolic and diastolic heart failure patients middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 23

Table 5 Various factors that affect death in systolic and diastolic heart

failure patients (univariate Cox regression) middotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddotmiddot 24

- iii -

- iv -

003

- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -

Department of Medicine

The Graduate School Yonsei University

( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -

SHF systolic heart failure DHF diastolic heart failure BSA body

surface area BP blood pressure HD heart disease CMP

cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010

History of Hypertension () 50(481) 36(529) 039

()

()

()

()

()

- 21 -

LVIDD diastolic left ventricular internal dimension LVIDS systolic left

ventricular internal dimension SHF systolic heart failureDHF diastolic

heart failure

SHF( N= 104) DHF( N= 68) p

Ejection fraction () 286plusmn72 498plusmn104 000

LVIDD (cm) 65plusmn09 57plusmn09 000

LVIDS (cm) 55plusmn10 41plusmn08 000

Left atrium (cm) 50plusmn08 52plusmn09 004

Relaxation abnormality () 35(337) 25(368) 062

Pseudonormal pattern () 6(58) 12(176) 001

Restrictive physiology () 23(221) 4(59) 0005

E velocity (cms) 94plusmn36 99plusmn36 053

A velocity (cms) 82plusmn31 102plusmn44 001

EA ratio 14plusmn10 10plusmn05 004

EE 194plusmn118 169plusmn132 037

LV mass index (gm2) 1449plusmn434 1312plusmn466 008

Wall motion score index 198plusmn105 149plusmn068 000

Mitral regurgitation () 42(477) 27(429) 055

- 22 -

SHF systolic heart failure DHF diastolic heart failure Na serum

sodium K serum potassium BUN Blood urea nitrogen HDL high

density lipoprotein LDL low density lipoprotein BNP brain natriuretic

peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -

SHF systolic heart failure DHF diastolic heart failure HTN Hypertension

Hb hemoglobin BUN Biliary urea nitrogen LA left atrium MACE major

adverse cardiac event WMSI wall motion score index fu follow up

Survival(N=48) Death(N=18) P value

DHF Age(years) 680plusmn116 771plusmn96 000

Hb 124plusmn28 116plusmn21 022

Weight(kg) 547plusmn121 529plusmn81 055

BUN 224plusmn119 246plusmn123 051

Creatinine 12plusmn07 15plusmn08 012

BNP(follow up) 5384plusmn5781 11743plusmn14322 015

LA size(cm) 53plusmn10 50plusmn07 029

Symptom(day) 29plusmn17 28plusmn15 085

WMSI 151plusmn061 149plusmn086 089

MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000

Furosemide use(Initial)() 15(313) 11(611) 002


SHF Age(years) 641plusmn146 741plusmn90 000









MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -

SHF systolic heart failure DHF diastolic heart

failure BUN Biliary urea nitrogen LA left atrium fu

follow up

Exp(B)950 CI for EXP(B)

Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993

Hemoglobin 0821 0702 0961

BUN 1036 1012 1060

Creatinine 1717 1114 2647

BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974

Initial ACEI use 0857 0409 1795

Initial ARB use 1085 0463 2541

dichlozid use(fu) 1199 0546 2635

Initial furosemide use 1479 0706 3098

DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -

SHF systolic heart failure DHF diastolic heart failure

983193

983193

983193

- i -
















- ii -











- iii -

- iv -

003

- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- i -
















- ii -











- iii -

- iv -

003

- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- ii -











- iii -

- iv -

003

- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- iii -

- iv -

003

- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- iv -

003

- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- v -

- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 1 -

- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 2 -

- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 3 -

- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 4 -

- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 5 -

- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 6 -

- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 7 -

- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 8 -

- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 9 -

1063

- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 10 -

- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 11 -

- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 12 -

- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 13 -

- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 14 -

- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 15 -

- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 16 -

- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 17 -

- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 18 -



( )

- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 19 -

707 025

003

_____________________________________________________________

- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 20 -



cardiomyopathy

Male () 56(538) 31(456) 029

Diabetes () 30(288) 21(309) 077

Smoking () 48(769) 23(338) 010


()

()

()

()

()

- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 21 -



heart failure

SHF( N= 104) DHF( N= 68) p















- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 22 -




peptide

SHF( N= 104) DHF( N= 68) p

Lab test

- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 23 -














MACE() 9(188) 5(277) 042

Sex(male)() 23(479) 6(333) 028

HTN() 21(417) 14(778) 002

ACEI use(Initial)() 35(729) 7(389) 001

Dichlozid use(fu)() 30(625) 4(222) 000












MACE 11(196) 19(514) 000

Sex(male)() 29(518) 23(622) 032

HTN() 23(411) 22(595) 008

ACEI use(Initial)() 36(643) 23(622) 083

Dichlozid use(fu)() 36(643) 23(622) 083


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 24 -



follow up


Lower Upper

SHF Age(year) 1047 1014 1081

Weight(day) 0963 0934 0993


BUN 1036 1012 1060


BNP(follow up) 1000 1000 1001

LA size(cm) 0416 0230 0751

Symptom(day) 0701 0505 0974





DHF Age(year) 1080 1026 1137

Weight(kg) 0969 0922 1018


BUN 1007 0971 1045


BNP(follow up) 1001 1000 1002

LA size(cm) 0863 0502 1483

Symptom(day) 0958 0711 1292





- 25 -


- 25 -


Date post:	22-Sep-2020
Category:	Documents
Upload:	others
View:	0 times
Download:	0 times

2009년 8월 일 - Yonsei University · 2020. 7. 3. · E/Aratio 1.4±1.0 1.0±0.5 0.04 E/E'...

Documents